Safety and tolerability of ELE-101 in healthy adults and people with depression
About this title
Read the official source — NCT05434156Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Liverpool and 1 more locationSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 84
- Sponsor
- Eleusis Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United Kingdom
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05434156
- Official title
Show the full official title
A Phase I, Randomised, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Intravenous Doses of ELE-101 in Healthy Adult Participants (Part 1) and Part 2, Open-Label Study to Evaluate a Range of Pharmacodynamic Effects of a Single Intravenous Dose of ELE-101 in Patients With Major Depressive Disorder.
Recruitment & locations
Liverpool · Manchester
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eleusis Therapeutics.
Does this study involve medication?
Yes. The study involves medication, including ELE-101 and ELE-101 Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
